keyword
MENU ▼
Read by QxMD icon Read
search

Broadly neutralizing antibody

keyword
https://www.readbyqxmd.com/read/29241550/structural-determination-of-the-broadly-reactive-anti-ighv1-69-anti-idiotypic-antibody-g6-and-its-idiotope
#1
Yuval Avnir, Kristina L Prachanronarong, Zhen Zhang, Shurong Hou, Eric C Peterson, Jianhua Sui, Hatem Zayed, Vinodh B Kurella, Andrew T McGuire, Leonidas Stamatatos, Brendan J Hilbert, Markus-Frederik Bohn, Timothy F Kowalik, Jeffrey D Jensen, Robert W Finberg, Jennifer P Wang, Margaret Goodall, Roy Jefferis, Quan Zhu, Nese Kurt Yilmaz, Celia A Schiffer, Wayne A Marasco
The heavy chain IGHV1-69 germline gene exhibits a high level of polymorphism and shows biased use in protective antibody (Ab) responses to infections and vaccines. It is also highly expressed in several B cell malignancies and autoimmune diseases. G6 is an anti-idiotypic monoclonal Ab that selectively binds to IGHV1-69 heavy chain germline gene 51p1 alleles that have been implicated in these Ab responses and disease processes. Here, we determine the co-crystal structure of humanized G6 (hG6.3) in complex with anti-influenza hemagglutinin stem-directed broadly neutralizing Ab D80...
December 12, 2017: Cell Reports
https://www.readbyqxmd.com/read/29239895/development-of-broad-neutralization-activity-in-shiv-infected-rhesus-macaques-after-long-term-infection
#2
Nan Gao, Wei Wang, Chu Wang, Tiejun Gu, Rui Guo, Bin Yu, Wei Kong, Chuan Qin, Elena E Giorgi, Zhiwei Chen, Samantha Townsley, Shiu-Lok Hu, Xianghui Yu, Feng Gao
OBJECTIVE: Non-human primates (NHPs) are the only animal model that can be used to evaluate protection efficacy of HIV-1 Env vaccines. However, whether broadly neutralizing antibodies (bnAbs) can be elicited in NHPs infected with simian/human immunodeficiency virus (SHIV) has not been fully understood. The objective of this study is to investigate whether broad neutralization activities were developed in SHIV-infected macaques after long-term infection as in humans. DESIGN: Neutralization breadth and specificities in plasmas from SHIV-infected macaques could be determined by analyzing a panel of tier 2 viruses and their mutants...
December 12, 2017: AIDS
https://www.readbyqxmd.com/read/29237847/a-trimeric-hiv-1-envelope-gp120-immunogen-induces-potent-and-broad-anti-v1v2-loop-antibodies-against-hiv-1-in-rabbits-and-rhesus-macaques
#3
Andrew T Jones, Venkateswarlu Chamcha, Sannula Kesavardhana, Xiaoying Shen, David Beaumont, Raksha Das, Linda S Wyatt, Celia C LaBranche, Sherry Stanfield-Oakley, Guido Ferrari, David C Montefiori, Bernard Moss, Georgia D Tomaras, Raghavan Varadarajan, Rama Rao Amara
Trimeric HIV-1 envelope (Env) immunogens are attractive due to their ability to display quaternary epitopes targeted by broadly neutralizing antibodies while obscuring unfavorable epitopes. Results from the RV144 trial highlighted the importance of vaccine induced HIV-1 Env V1V2 directed antibodies, with key regions of the V2 loop as targets for vaccine-mediated protection. We recently reported that a trimeric JRFL-gp120 immunogen, generated by inserting a N-terminal trimerization domain in the V1 loop region of a cyclically permuted gp120 (cycP-gp120), induces neutralizing activity against multiple tier-2 HIV-1 isolates in guinea pigs in a DNA prime/protein boost approach...
December 13, 2017: Journal of Virology
https://www.readbyqxmd.com/read/29237833/neutralizing-activity-of-broadly-neutralizing-anti-hiv-1-antibodies-against-clade-b-clinical-isolates-produced-in-peripheral-blood-mononuclear-cells
#4
Yehuda Z Cohen, Julio C C Lorenzi, Michael S Seaman, Lilian Nogueira, Till Schoofs, Lisa Krassnig, Allison Butler, Katrina Millard, Tomas Fitzsimons, Xiaoju Daniell, Juan P Dizon, Irina Shimeliovich, David C Montefiori, Marina Caskey, Michel C Nussenzweig
Recently discovered broadly neutralizing anti-HIV-1 antibodies (bNAbs) demonstrate extensive breadth and potency against diverse HIV-1 strains, and represent a promising approach for the treatment and prevention of HIV-1 infection. The breadth and potency of these antibodies have primarily been evaluated using panels of HIV-1 Env-pseudotyped viruses produced in 293T cells expressing molecularly cloned Envs. Here we report on the ability of 5 bNAbs currently in clinical development to neutralize circulating primary HIV-1 isolates derived from peripheral blood mononuclear cells (PBMC), and compare the results to the pseudovirus panels used to characterize the bNAbs...
December 13, 2017: Journal of Virology
https://www.readbyqxmd.com/read/29237828/identification-of-novel-structural-determinants-in-mw965-env-that-regulate-the-neutralization-phenotype-and-conformational-masking-potential-of-primary-hiv-1-isolates
#5
Zakiya M Qualls, Alok Choudhary, William Honnen, Raja Prattipati, James E Robinson, Abraham Pinter
The subtype C HIV-1 isolate MW965.26 is a highly neutralization-sensitive tier-1a primary isolate that is widely used in vaccine studies, but the basis for the sensitive neutralization phenotype of this isolate is not known. Substituting the MW965.26 V1/V2 domain into a neutralization-sensitive SF162 Env clone resulted in high resistance to standard anti-V3 monoclonal antibodies, demonstrating that this region possessed strong masking activity in a standard Env backbone and indicating that determinants elsewhere in MW965...
December 13, 2017: Journal of Virology
https://www.readbyqxmd.com/read/29234320/increasing-the-clinical-potential-and-applications-of-anti-hiv-antibodies
#6
REVIEW
Casey K Hua, Margaret E Ackerman
Preclinical and early human clinical studies of broadly neutralizing antibodies (bNAbs) to prevent and treat HIV infection support the clinical utility and potential of bNAbs for prevention, postexposure prophylaxis, and treatment of acute and chronic infection. Observed and potential limitations of bNAbs from these recent studies include the selection of resistant viral populations, immunogenicity resulting in the development of antidrug (Ab) responses, and the potentially toxic elimination of reservoir cells in regeneration-limited tissues...
2017: Frontiers in Immunology
https://www.readbyqxmd.com/read/29230222/single-dose-of-consensus-hemagglutinin-based-virus-like-particles-vaccine-protects-chickens-against-divergent-h5-subtype-influenza-viruses
#7
Peipei Wu, Jihu Lu, Xuehua Zhang, Mei Mei, Lei Feng, Daxin Peng, Jibo Hou, Sang-Moo Kang, Xiufan Liu, Yinghua Tang
The H5 subtype highly pathogenic avian influenza (HPAI) virus is one of the greatest threats to global poultry industry. To develop broadly protective H5 subunit vaccine, a recombinant consensus HA sequence (rHA) was constructed and expressed in virus-like particles (rHA VLPs) in the baculovirus-insect cell system. The efficacy of the rHA VLPs vaccine with or without immunopotentiator (CVCVA5) was assessed in chickens. Compared to the commercial Re6 or Re6-CVCVA5 vaccines, single dose immunization of chickens with rHA VLPs or rHA-CVCVA5 vaccines induced higher levels of serum hemagglutinin inhibition titers and neutralization titers, mucosal antibodies, IFN-γ and IL-4 cytokines in sera, and cytotoxic T lymphocyte responses...
2017: Frontiers in Immunology
https://www.readbyqxmd.com/read/29229811/correction-for-giang-et-al-human-broadly-neutralizing-antibodies-to-the-envelope-glycoprotein-complex-of-hepatitis-c-virus
#8
(no author information available yet)
No abstract text is available yet for this article.
December 11, 2017: Proceedings of the National Academy of Sciences of the United States of America
https://www.readbyqxmd.com/read/29226015/conserved-hiv-epitopes-for-an-effective-hiv-vaccine
#9
Bikash Sahay, Cuong Q Nguyen, Janet K Yamamoto
Despite major advances in antiretroviral therapy against HIV-1, an effective HIV vaccine is urgently required to reduce the number of new cases of HIV infections in the world. Vaccines are the ultimate tool in the medical arsenal to control and prevent the spread of infectious diseases such as HIV/AIDS. Several failed phase-IIb to -III clinical vaccine trials against HIV-1 in the past generated a plethora of information that could be used for better designing of an effective HIV vaccine in the future. Most of the tested vaccine candidates produced strong humoral responses against the HIV proteins; however, failed to protect due to: 1) the low levels and the narrow breadth of the HIV-1 neutralizing antibodies and the HIV-specific antibody-dependent Fc-mediated effector activities, 2) the low levels and the poor quality of the anti-HIV T-cell responses, and 3) the excessive responses to immunodominant non-protective HIV epitopes, which in some cases blocked the protective immunity and/or enhanced HIV infection...
August 2017: Journal of Clinical & Cellular Immunology
https://www.readbyqxmd.com/read/29226013/novel-therapeutic-approach-for-inhibition-of-hiv-1-using-cell-penetrating-peptide-and-bacterial-toxins
#10
Steven Samuels, Zainab Alwan, Marceline Egnin, Jessie Jaynes, Terry D Connell, Gregory C Bernard, Toufic Nashar
Despite advancements in our understanding of HIV-1 pathogenesis, critical virus components for immunity, vaccines trials, and drugs development, challenges remain in the fight against HIV-1. Of great importance is the inhibitory function of microbicidal cell penetrating peptides and bacterial toxins that interfere with production and neutralize infection of HIV-1 particles. We demonstrate that the neutralizing activity of a cationic 18 amino acids peptide, is similar to a broadly neutralizing human antibody, and inhibits production of two HIV-1 strains in human cell lines...
October 2017: Journal of AIDS & Clinical Research
https://www.readbyqxmd.com/read/29222332/stabilization-of-the-gp120-v3-loop-through-hydrophobic-interactions-reduces-the-immunodominant-v3-directed-non-neutralizing-response-to-hiv-1-envelope-trimers
#11
Steven W de Taeye, Alba Torrents de la Peña, Andrea Vecchione, Enzo Scutigliani, Kwinten Sliepen, Judith A Burger, Patricia van der Woude, Anna Schorcht, Edith E Schermer, Marit J van Gils, Celia C LaBranche, David C Montefiori, Ian A Wilson, John P Moore, Andrew B Ward, Rogier W Sanders
To provide protective immunity against circulating primary HIV-1 strains, a vaccine most likely has to induce broadly neutralizing antibodies (bNAbs) to the HIV-1 envelope (Env) glycoprotein spike. Recombinant Env trimers such as the prototype BG505 SOSIP.664 that closely mimic the native Env spike can induce autologous neutralizing antibodies (NAbs) against relatively resistant (tier-2) primary viruses. Ideally, Env immunogens should present bNAb epitopes, but limit the presentation of immunodominant non-NAb epitopes that might induce off-target and potentially interfering responses...
December 8, 2017: Journal of Biological Chemistry
https://www.readbyqxmd.com/read/29218117/basis-and-statistical-design-of-the-passive-hiv-1-antibody-mediated-prevention-amp-test-of-concept-efficacy-trials
#12
Peter B Gilbert, Michal Juraska, Allan C deCamp, Shelly Karuna, Srilatha Edupuganti, Nyaradzo Mgodi, Deborah J Donnell, Carter Bentley, Nirupama Sista, Philip Andrew, Abby Isaacs, Yunda Huang, Lily Zhang, Edmund Capparelli, Nidhi Kochar, Jing Wang, Susan H Eshleman, Kenneth H Mayer, Craig A Magaret, John Hural, James G Kublin, Glenda Gray, David C Montefiori, Margarita M Gomez, David N Burns, Julie McElrath, Julie Ledgerwood, Barney S Graham, John R Mascola, Myron Cohen, Lawrence Corey
Background: Anti-HIV-1 broadly neutralizing antibodies (bnAbs) have been developed as potential agents for prevention of HIV-1 infection. The HIV Vaccine Trials Network and the HIV Prevention Trials Network are conducting the Antibody Mediated Prevention (AMP) trials to assess whether, and how, intravenous infusion of the anti-CD4 binding site bnAb, VRC01, prevents HIV-1 infection. These are the first test-of-concept studies to assess HIV-1 bnAb prevention efficacy in humans. Methods: The AMP trials are two parallel phase 2b HIV-1 prevention efficacy trials conducted in two cohorts: 2700 HIV-uninfected men and transgender persons who have sex with men in the United States, Peru, Brazil, and Switzerland; and 1500 HIV-uninfected sexually active women in seven countries in sub-Saharan Africa...
January 2017: Statistical Communications in Infectious Diseases
https://www.readbyqxmd.com/read/29212932/minor-capsid-protein-l2-polytope-induces-broad-protection-against-oncogenic-and-mucosal-human-papillomaviruses
#13
Somayeh Pouyanfard, Gloria Spagnoli, Lorenzo Bulli, Kathrin Balz, Fan Yang, Caroline Odenwald, Hanna Seitz, Filipe C Mariz, Angelo Bolchi, Simone Ottonello, Martin Müller
The amino terminus of the human papillomavirus minor capsid protein L2 contains a major cross-neutralization epitope which provides the basis for the development of a broadly protecting HPV vaccine. Wide range of protection against different HPV types would eliminate one of the major drawbacks of the commercial, L1 based prophylactic vaccines. Previously, we have reported that insertion of the L2 epitope into a scaffold composed of bacterial thioredoxin protein generates a potent antigen inducing comprehensive protection against different animal and human papillomaviruses...
December 6, 2017: Journal of Virology
https://www.readbyqxmd.com/read/29208932/mouse-papillomavirus-infection-persists-in-mucosal-tissues-of-an-immunocompetent-mouse-strain-and-progresses-to-cancer
#14
Nancy M Cladel, Lynn R Budgeon, Karla K Balogh, Timothy K Cooper, Sarah A Brendle, Neil D Christensen, Todd D Schell, Jiafen Hu
Mouse papillomavirus has shown broad tissue tropism in nude mice. Previous studies have tested cutaneous infections in different immunocompromised and immunocompetent mouse strains. In the current study, we examined mucosal infection in several immunocompetent and immunocompromised mouse strains. Viral DNA was monitored periodically by Q-PCR of lavage samples. Immunohistochemistry and in situ hybridization were used to determine viral capsid protein and viral DNA respectively. All athymic nude mouse strains showed active infections at both cutaneous and mucosal sites...
December 5, 2017: Scientific Reports
https://www.readbyqxmd.com/read/29194123/anti-hiv-1-antibody-dependent-cellular-cytotoxicity-is-there-more-to-antibodies-than-neutralization
#15
Wen Shi Lee, Stephen J Kent
PURPOSE OF REVIEW: An increasing body of evidence suggests that nonneutralizing Fc effector functions including antibody-dependent cellular cytotoxicity (ADCC) contribute to protection against HIV-1 acquisition. We discuss recent advances in anti-HIV-1 ADCC research with a particular focus on ADCC mediated by Env-specific antibodies in vitro and in vivo, the curative potential of HIV-1-specific ADCC antibodies and the mechanisms of HIV-1 resistance to ADCC. RECENT FINDINGS: ADCC activities of broadly neutralizing and nonneutralizing monoclonal antibody panels were recently characterized in vitro against several lab-adapted and primary isolates of HIV-1...
November 30, 2017: Current Opinion in HIV and AIDS
https://www.readbyqxmd.com/read/29187855/cd4-binding-site-directed-cross-neutralizing-scfv-monoclonals-from-hiv-1-subtype-c-infected-indian-children
#16
Sanjeev Kumar, Rajesh Kumar, Lubina Khan, Muzamil Ashraf Makhdoomi, Ramachandran Thiruvengadam, Madhav Mohata, Mudit Agarwal, Rakesh Lodha, Sushil Kumar Kabra, Subrata Sinha, Kalpana Luthra
Progression of human immunodeficiency virus type-1 (HIV-1) infection in children is faster than adults. HIV-1 subtype C is responsible for more than 50% of the infections globally and more than 90% infections in India. To date, there is no effective vaccine against HIV-1. Recent animal studies and human Phase I trials showed promising results of the protective effect of anti-HIV-1 broadly neutralizing antibodies (bnAbs). Interaction between CD4 binding site (CD4bs) on the HIV-1 envelope glycoprotein and CD4 receptor on the host immune cells is the primary event leading to HIV-1 infection...
2017: Frontiers in Immunology
https://www.readbyqxmd.com/read/29187732/structural-basis-of-respiratory-syncytial-virus-subtype-dependent-neutralization-by-an-antibody-targeting-the-fusion-glycoprotein
#17
Daiyin Tian, Michael B Battles, Syed M Moin, Man Chen, Kayvon Modjarrad, Azad Kumar, Masaru Kanekiyo, Kevin W Graepel, Noor M Taher, Anne L Hotard, Martin L Moore, Min Zhao, Zi-Zheng Zheng, Ning-Shao Xia, Jason S McLellan, Barney S Graham
A licensed vaccine for respiratory syncytial virus (RSV) is unavailable, and passive prophylaxis with the antibody palivizumab is restricted to high-risk infants. Recently isolated antibodies 5C4 and D25 are substantially more potent than palivizumab, and a derivative of D25 is in clinical trials. Here we show that unlike D25, 5C4 preferentially neutralizes subtype A viruses. The crystal structure of 5C4 bound to the RSV fusion (F) protein reveals that the overall binding mode of 5C4 is similar to that of D25, but their angles of approach are substantially different...
November 30, 2017: Nature Communications
https://www.readbyqxmd.com/read/29187598/epitope-focused-immunogens-against-the-cd4-binding-site-of-hiv-1-envelope-protein-induce-neutralizing-antibodies-against-auto-and-heterologous-viruses
#18
Hua Wang, Xiangjun Chen, Dianhong Wang, Chen Yao, Qian Wang, Jiayu Xie, Xuanling Shi, Ye Xiang, Wanli Liu, Linqi Zhang
Recent discoveries of broadly neutralizing antibodies (bnAbs) in HIV-1-infected individuals have led to the identification of several major ″vulnerable sites″ on the HIV-1 envelope (Env) glycoprotein. These sites have provided precise targets for HIV-1 vaccine development, but identifying and utilizing many of these targets remains technically challenging. Using a yeast surface display-based approach, we sought to identify epitope-focused antigenic domains (EADs) containing one of the ″vulnerable sites″, the CD4-binding site (CD4bs), through screening and selection of a combinatorial antigen library of the HIV-1 Env glycoprotein with the CD4bs bnAb VRC01...
November 29, 2017: Journal of Biological Chemistry
https://www.readbyqxmd.com/read/29187545/novel-insect-specific-eilat-virus-based-chimeric-vaccine-candidates-provide-durable-mono-and-multi-valent-single-dose-protection-against-lethal-alphavirus-challenge
#19
Jesse H Erasmus, Robert L Seymour, Jason T Kaelber, Dal Y Kim, Grace Leal, Michael B Sherman, Ilya Frolov, Wah Chiu, Scott C Weaver, Farooq Nasar
Most alphaviruses are mosquito-borne and exhibit a broad host range, infecting many different vertebrates including birds, rodents, equids, humans and nonhuman primates. Recently, a host-restricted, mosquito-borne alphavirus, Eilat virus (EILV), was described with an inability to infect vertebrate cells based on defective attachment and/or entry as well as a lack of genomic RNA replication. We investigated the utilization of EILV recombinant technology as a vaccine platform against eastern (EEEV) and Venezuelan equine encephalitis viruses (VEEV), two important pathogens of humans and domesticated animals...
November 29, 2017: Journal of Virology
https://www.readbyqxmd.com/read/29173180/the-neutralizing-antibody-response-to-the-hiv-1-env-protein
#20
Penny L Moore
BACKGROUND: A vaccine able to elicit broadly neutralizing antibodies capable of blocking infection by global viruses has not been achieved, and remains a key public health challenge. OBJECTIVE: During infection, a robust strain-specific neutralizing response develops in most people, but only a subset of infected people develop broadly neutralizing antibodies. Understanding how and why these broadly neutralizing antibodies develop has been a focus of the HIV-1 vaccine field for many years, and has generated extraordinary insights into the neutralizing response to HIV-1 infection...
November 24, 2017: Current HIV Research
keyword
keyword
34044
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"